Figure 2.

Gemcitabine-eluting membrane (GEM) implantation inhibits EGFR signaling in xenograft tumors. (A,B) Western blot analysis of phospho-EGFR, EGFR, Ras, PI3K, phospho-PDK, PDK, phospho-AKT, AKT, phospho-GSK3β, and GSK3β at the bottom and top of the indicated tumors from the GEM-implanted and control groups. (C) p53, p21, cyclin D1, and cyclin B expression was evaluated by Western blot analysis in SCK and PANC-1 tumors after implantation of the GEM containing the indicated concentrations of gemcitabine. (D) Proteins derived from tumor lysates obtained from the bottom and top of SCK tumors were subjected to Western blot analysis using the indicated antibodies.